KRRO Korro Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1703647 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-82.5%
TTM net income YoY-20.0%
TTM EPS YoY5.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8,467.3%
Net margin-8,214.5%
FCF margin-4,943.8%
EBITDA margin-8,325.8%
Returns
ROE-113.3%
ROA-68.5%
ROIC (approx.)-140.5%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets40.3%
Debt / equity0.00x
Current ratio7.30x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.60x
Accruals ratio-27.4%
Payout ratio—
Capex / revenue13.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $6.39M | $2.27M |
| R&D expense | $65.58M | $63.64M |
| SG&A expense | $28.16M | $30.55M |
| Operating income | -$121.86M | -$91.91M |
| Pretax income | -$116.62M | -$83.44M |
| Income tax | $637,000 | $141,000 |
| Net income | -$117.26M | -$83.58M |
| EBITDA | -$117.58M | -$88.34M |
| EPS (basic) | -12.48 | -9.37 |
| EPS (diluted) | -12.48 | -9.37 |
| Weighted avg. shares (diluted) | 9.40M | 8.92M |
| Balance sheet | ||
| Cash & equivalents | $21.82M | $55.64M |
| Short-term investments | $53.33M | $70.45M |
| Current assets | $82.37M | $131.53M |
| PP&E, net | $8.16M | $27.71M |
| Total assets | $113.51M | $226.24M |
| Current liabilities | $11.94M | $14.96M |
| Total liabilities | $62.07M | $65.83M |
| Shareholders' equity | $51.44M | $160.41M |
| Shares outstanding | 9.42M | 9.38M |
| Cash flow statement | ||
| Operating cash flow | -$78.56M | -$60.07M |
| Capital expenditure | $518,000 | $17.90M |
| Free cash flow | -$79.08M | -$77.98M |
| Investing cash flow | $43.99M | -$123.35M |
| Financing cash flow | $685,000 | $69.36M |
| Depreciation & amortization | $4.28M | $3.56M |
| Stock-based compensation | $7.66M | $4.46M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.